¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀåÀº 2022³â ¾à 20¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2023-2030³â µ¿¾È 9.0% ÀÌ»óÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¾Ë·¹¸£±â ¸é¿ª¿ä¹ýÀº ¾Ë·¹¸£±â¿¡ ´ëÇÑ ÀÇÇÐÀû Ä¡·á¹ýÀÔ´Ï´Ù. ²É°¡·ç, Áøµå±â, ¹Ý·Áµ¿¹°ÀÇ ºñµë, ƯÁ¤ °ïÃæ µ¶°ú °°Àº ƯÁ¤ ¾Ë·¹¸£°Õ¿¡ ´ëÇÑ ¸é¿ª ü°èÀÇ °¨ÀÛÀ» ¸ñÇ¥·Î ÇÏ´Â Àå±âÀûÀÎ Ä¡·á¹ýÀÔ´Ï´Ù. ¾Ë·¹¸£±â ¸é¿ª¿ä¹ýÀÇ ¸ñÀûÀº ¾Ë·¹¸£±â Ç׿ø¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀÀ» º¯È½ÃÄÑ ¾Ë·¹¸£±â Áõ»óÀ» ¿ÏÈÇÏ´Â °ÍÀÔ´Ï´Ù. ¾Ë·¹¸£±â¼º ºñ¿°(²É°¡·ç ¾Ë·¹¸£±â), ¾Ë·¹¸£±â¼º õ½Ä, °ïÃæµ¶ ¾Ë·¹¸£±â Ä¡·á¿¡ È¿°úÀûÀÔ´Ï´Ù. ¾Ë·¹¸£±â ¿¹¹æÁÖ»ç´Â Ä¡·á Á¾·á ÈÄ¿¡µµ Àå±â°£ Áõ»óÀ» ¿ÏÈÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀåÀº ´Ù¾çÇÑ Á¾·ùÀÇ ¾Ë·¹¸£±â ºÎ´ã Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù.
American College of Allergy, Asthma &ImmunologyÀÇ Á¤º¸¿¡ µû¸£¸é, ¸Å³â 5,000¸¸ ¸í ÀÌ»óÀÇ ¹Ì±¹ÀÎÀÌ ¾Ë·¹¸£±â¸¦ ¾Î°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ½Ì±ÛÄɾî(SingleCare)°¡ 2022³â 1¿ù¿¡ ¹ßÇ¥ÇÑ Çмú ³í¹®¿¡ µû¸£¸é, ¸Å³â 5õ¸¸ ¸í ÀÌ»óÀÇ ¹Ì±¹ÀÎÀÌ ¾î¶² Á¾·ùÀÇ ¾Ë·¹¸£±â¸¦ °æÇèÇϰí ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¸¶Âù°¡Áö·Î 2050³â Àεµ Àü¿ªÀÇ ³ëÀΠõ½Ä ȯÀÚ ¼ö´Â ¾à 2,540¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¾Ë·¹¸£±â´Â ¹Ì±¹¿¡¼ 6¹øÂ°·Î ÈçÇÑ ¸¸¼ºÁúȯÀ¸·Î ²ÅÈ÷°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Ì±ÛÄɾ 2021³â¿¡ ½Ç½ÃÇÑ ¼³¹®Á¶»ç¿¡ µû¸£¸é, ¾Ë·¹¸£±â°¡ ÀÖ´Â ÀÀ´äÀÚÀÇ 82.0%°¡ ¹Ì±¹¿¡¼ ¾Ë·¹¸£±â°¡ »îÀÇ Áú¿¡ ¿µÇâÀ» ¹ÌÄ£´Ù°í »ý°¢ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌó·³ Àü ¼¼°èÀûÀ¸·Î ¾Ë·¹¸£±â À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼³ÇÏ Åõ¿© Á¦Á¦ÀÇ ±â¼ú ¹ßÀü°ú °·ÂÇÑ Á¦Ç° ÆÄÀÌÇÁ¶óÀÎÀÇ Á¸Àç´Â ½ÃÀå ¼ºÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¾Ë·¹¸£±â ¸é¿ª¿ä¹ýÀÇ ³ôÀº ¿¬±¸ ºñ¿ë, ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý »ç¿ë¿¡ µû¸¥ ´ÜÁ¡, ´ëü Ä¡·á¹ýÀÇ °¡¿ë¼ºÀº 2023-2030³â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¼¼°è ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀå Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« µîÀÔ´Ï´Ù. ºÏ¹Ì´Â ÁÖ¿ä ½ÃÀå ÁøÀÔ ±â¾÷ÀÇ ¿ìÀ§, ¾Ë·¹¸£±â ÁúȯÀÇ Áõ°¡, ÀÌ Áö¿ª¿¡¼ÀÇ Á¦Ç° Ãâ½Ã Ȱµ¿ Áõ°¡·Î ÀÎÇØ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áúº´ ¹ßº´·ü Áõ°¡, ÁÖ¿ä ½ÃÀå Âü¿©ÀÚµéÀÇ »ç¾÷ È®Àå, Áö¿ª ³» ÀÎ½Ä Á¦°í ÇÁ·Î±×·¥ Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ °¡Àå ºü¸¥ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ Á¶»çÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¸î ³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû, ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.
¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï »óȲ°ú Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚµéÀÌ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ¼¼°èÀÇ ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
- Á¶»ç ¸ñÀû
- ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
- Á¶»ç ´ë»ó ¿¬µµ
- ÅëÈ È¯»êÀ²
Á¦3Àå ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀå ¿ªÇÐ
- ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀåÀÇ ¿µÇ⠺м®(2020-2030³â)
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- °¢Á¾ ¾Ë·¹¸£±â ºÎ´ã Áõ°¡
- ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
- ½ÃÀå °úÁ¦
- ¾Ë·¹¸£±â ¸é¿ª¿ä¹ýÀÇ °íºñ¿ë
- ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý
- ½ÃÀå ±âȸ
- ¼³ÇÏ Åõ¿© Á¦Á¦ÀÇ ±â¼úÀû Áøº¸
- °·ÂÇÑ Á¦Ç° ÆÄÀÌÇÁ¶óÀÎÀÇ Á¸Àç
Á¦4Àå ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀå »ê¾÷ ºÐ¼®
- Porter's 5 Force ¸ðµ¨
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ±¸¸ÅÀÚÀÇ ±³¼··Â
- ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è
- Porter's 5 Force ¿µÇ⠺м®
- PEST ºÐ¼®
- Á¤Ä¡Àû
- °æÁ¦
- »çȸ
- 񃬣
- ȯ°æ
- ¹ý·ü
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- COVID-19 ¿µÇ⠺м®
- ÆÄ±«Àû µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ °üÁ¡
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð°ú Á¦¾È
Á¦5Àå ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀå : Ä¡·á À¯Çüº°
- ½ÃÀå ÇöȲ
- ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀå : Ä¡·á À¯Çüº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
- ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀå : Ä¡·á À¯Çüº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
- ÇÇÇÏ ¸é¿ª¿ä¹ý(SCIT)
- ¼³ÇÏ ¸é¿ª¿ä¹ý(SLIT)
Á¦6Àå ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀå : ¾Ë·¹¸£±â À¯Çüº°
- ½ÃÀå ÇöȲ
- ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀå : ¾Ë·¹¸£±â À¯Çüº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
- ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀå : ¾Ë·¹¸£±â À¯Çüº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
- ¾Ë·¹¸£±â¼º ºñ¿°
- ¾Ë·¹¸£±â¼º õ½Ä
- ±âŸ
Á¦7Àå ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀå : À¯Åë ä³Îº°
- ½ÃÀå ÇöȲ
- ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀå : À¯Åë ä³Îº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
- ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀå : À¯Åë ä³Îº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
Á¦8Àå ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ¼¼°è ½ÃÀå : Áö¿ªº° ºÐ¼®
- ÁÖ¿ä ±¹°¡
- ÁÖ¿ä ½ÅÈï ±¹°¡
- ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀå, Áö¿ªº° ½ÃÀå ÇöȲ
- ºÏ¹Ì
- ¹Ì±¹
- Ä¡·á À¯Çü, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- ¾Ë·¹¸£±â À¯Çü, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- À¯Åë ä³Îº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- ij³ª´Ù
- À¯·´ÀÇ ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀå ÇöȲ
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀå ÇöȲ
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¾Ë·¹¸£±â ¸é¿ª¿ä¹ý ½ÃÀå ÇöȲ
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦9Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ °³¿ä
- Torii Pharmaceutical Co., Ltd.
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍ °¡¿ë¼º¿¡ µû¶ó ´Ù¸§)
- Á¦Ç° °³¿ä
- ALK-Abello A/S
- Allergy Therapeutics
- Biomay AG
- Allovate, LLC
- HAL Allergy Group
- Jubliant Pharma(Hollister Allergy)
- Leti Pharma
- Merck KGaA(Allergopharma)
- Stallergenes Greer
Á¦10Àå Á¶»ç °úÁ¤
- Á¶»ç °úÁ¤
- µ¥ÀÌÅÍ ±¤¾÷
- ºÐ¼®
- ½ÃÀå ÃßÁ¤
- °ËÁõ
- ÃâÆÇ
- Á¶»ç ¼Ó¼º
- Á¶»ç °¡Á¤
ksm 23.11.28
Global Allergy Immunotherapy Market is valued at approximately USD 2.07 billion in 2022 and is anticipated to grow with a growth rate of more than 9.0% over the forecast period 2023-2030. Allergy immunotherapy is a medical treatment for allergies. It is a long-term therapy that aims to desensitize a person's immune system to specific allergens, such as pollen, dust mites, pet dander, or certain insect venoms. The goal of allergy immunotherapy is to modify the immune response to allergens, leading to a reduction in allergy symptoms. It can be effective in treating allergic rhinitis (hay fever), allergic asthma, and insect venom allergies. Allergy shots can provide long-term relief, even after the treatment is completed. The Allergy Immunotherapy market is expanding because of factors such as the increasing burden of various types of allergies and rising demand for personalized medicine.
According to Information form the American College of Allergy, Asthma & Immunology, more than 50 million Americans suffer from allergies each year. In addition, for instance, a journal paper published by SingleCare in January 2022 estimates that more than 50.0 million Americans experience an allergy of some form each year. Similarly, The number of cases of asthma in Indian senior citizens across the India in 2050 was anticipated to be about 25.4 million cases. Furthermore, it noted that allergies rank as the sixth-most prevalent chronic illness in the US. In addition, a survey conducted by SingleCare in 2021 found that 82.0% of respondents who had allergies felt their allergies had an impact on their quality of life in the US. Thus, rising incidence of allergies across the regions is driving the market growth. In addition, technological advancements in sublingual dosage formulations and presence of strong product pipeline are creating a lucrative opportunity to the market growth. However, the high cost of allergy immunotherapy research and drawbacks associated with the use of allergy immunotherapy and availability of alternative treatments stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Allergy Immunotherapy Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the dominance of key market players, rising prevelance of allergy disorders, rising number of product launch activities in the region. Whereas, Asia Pacific region is projected to have fastest growth owing to factors such as rising disease prevelance, rising expansion by key market players in the region as well as rising number of awareness programs in the region.
Major market player included in this report are:
- Torii Pharmaceutical Co., Ltd.
- ALK-Abello A/S
- Allergy Therapeutics
- Biomay AG
- Allovate, LLC
- HAL Allergy Group
- Jubliant Pharma (Hollister Allergy)
- Leti Pharma
- Merck KGaA (Allergopharma)
- Stallergenes Greer
Recent Developments in the Market:
- In January 2023, HollisterStier Allergy unveiled Ultrafiltered Dog, its most recent product innovation. Patients who are sensitive to dogs can be diagnosed and treated successfully with the product.
- In June 2022, ALK began a phase I clinical research in North America for their brand-new sublingual tablet intended to treat peanut allergy.
Global Allergy Immunotherapy Market Report Scope:
- Historical Data - 2020 - 2021
- Base Year for Estimation - 2022
- Forecast period - 2023-2030
- Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered - Treatment Type, Allery Type, Distribution Channel, Region
- Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
- Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Treatment Type:
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
By Allergy Type:
- Allergic rhinitis
- Allergic asthma
- Others
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region:
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
- 1.2.1. Allergy Immunotherapy Market, by region, 2020-2030 (USD Billion)
- 1.2.2. Allergy Immunotherapy Market, by Treatment Type, 2020-2030 (USD Billion)
- 1.2.3. Allergy Immunotherapy Market, by Allergy Type, 2020-2030 (USD Billion)
- 1.2.4. Allergy Immunotherapy Market, by Distribution Channel, 2020-2030 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Allergy Immunotherapy Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Industry Evolution
- 2.2.2. Scope of the Study
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Allergy Immunotherapy Market Dynamics
- 3.1. Allergy Immunotherapy Market Impact Analysis (2020-2030)
- 3.1.1. Market Drivers
- 3.1.1.1. Increasing burden of various types of allergies
- 3.1.1.2. Rising demand for personalized medicine
- 3.1.2. Market Challenges
- 3.1.2.1. High Cost of Allergy Immunotherapy
- 3.1.2.2. Allergy Immunotherapy
- 3.1.3. Market Opportunities
- 3.1.3.1. Technological advancements in sublingual dosage formulations
- 3.1.3.2. Presence of strong product pipeline
Chapter 4. Global Allergy Immunotherapy Market: Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. Porter's 5 Force Impact Analysis
- 4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economic
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. COVID-19 Impact Analysis
- 4.7. Disruptive Trends
- 4.8. Industry Expert Perspective
- 4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Allergy Immunotherapy Market, by Treatment Type
- 5.1. Market Snapshot
- 5.2. Global Allergy Immunotherapy Market by Treatment Type, Performance - Potential Analysis
- 5.3. Global Allergy Immunotherapy Market Estimates & Forecasts by Treatment Type 2020-2030 (USD Billion)
- 5.4. Allergy Immunotherapy Market, Sub Segment Analysis
- 5.4.1. Subcutaneous Immunotherapy (SCIT)
- 5.4.2. Sublingual Immunotherapy (SLIT)
Chapter 6. Global Allergy Immunotherapy Market, by Allergy Type
- 6.1. Market Snapshot
- 6.2. Global Allergy Immunotherapy Market by Allergy Type, Performance - Potential Analysis
- 6.3. Global Allergy Immunotherapy Market Estimates & Forecasts by Allergy Type 2020-2030 (USD Billion)
- 6.4. Allergy Immunotherapy Market, Sub Segment Analysis
- 6.4.1. Allergic rhinitis
- 6.4.2. Allergic asthma
- 6.4.3. Others
Chapter 7. Global Allergy Immunotherapy Market, by Distribution Channel
- 7.1. Market Snapshot
- 7.2. Global Allergy Immunotherapy Market by Distribution Channel, Performance - Potential Analysis
- 7.3. Global Allergy Immunotherapy Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
- 7.4. Allergy Immunotherapy Market, Sub Segment Analysis
- 7.4.1. Hospital Pharmacy
- 7.4.2. Retail Pharmacy
- 7.4.3. Online Pharmacy
Chapter 8. Global Allergy Immunotherapy Market, Regional Analysis
- 8.1. Top Leading Countries
- 8.2. Top Emerging Countries
- 8.3. Allergy Immunotherapy Market, Regional Market Snapshot
- 8.4. North America Allergy Immunotherapy Market
- 8.4.1. U.S. Allergy Immunotherapy Market
- 8.4.1.1. Treatment Type breakdown estimates & forecasts, 2020-2030
- 8.4.1.2. Allergy Type breakdown estimates & forecasts, 2020-2030
- 8.4.1.3. Distribution Channel breakdown estimates & forecasts, 2020-2030
- 8.4.2. Canada Allergy Immunotherapy Market
- 8.5. Europe Allergy Immunotherapy Market Snapshot
- 8.5.1. U.K. Allergy Immunotherapy Market
- 8.5.2. Germany Allergy Immunotherapy Market
- 8.5.3. France Allergy Immunotherapy Market
- 8.5.4. Spain Allergy Immunotherapy Market
- 8.5.5. Italy Allergy Immunotherapy Market
- 8.5.6. Rest of Europe Allergy Immunotherapy Market
- 8.6. Asia-Pacific Allergy Immunotherapy Market Snapshot
- 8.6.1. China Allergy Immunotherapy Market
- 8.6.2. India Allergy Immunotherapy Market
- 8.6.3. Japan Allergy Immunotherapy Market
- 8.6.4. Australia Allergy Immunotherapy Market
- 8.6.5. South Korea Allergy Immunotherapy Market
- 8.6.6. Rest of Asia Pacific Allergy Immunotherapy Market
- 8.7. Latin America Allergy Immunotherapy Market Snapshot
- 8.7.1. Brazil Allergy Immunotherapy Market
- 8.7.2. Mexico Allergy Immunotherapy Market
- 8.8. Middle East & Africa Allergy Immunotherapy Market
- 8.8.1. Saudi Arabia Allergy Immunotherapy Market
- 8.8.2. South Africa Allergy Immunotherapy Market
- 8.8.3. Rest of Middle East & Africa Allergy Immunotherapy Market
Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.1.1. Company 1
- 9.1.2. Company 2
- 9.1.3. Company 3
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. Torii Pharmaceutical Co., Ltd.
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Product Summary
- 9.3.1.5. Recent Developments
- 9.3.2. ALK-Abello A/S
- 9.3.3. Allergy Therapeutics
- 9.3.4. Biomay AG
- 9.3.5. Allovate, LLC
- 9.3.6. HAL Allergy Group
- 9.3.7. Jubliant Pharma (Hollister Allergy)
- 9.3.8. Leti Pharma
- 9.3.9. Merck KGaA (Allergopharma)
- 9.3.10. Stallergenes Greer
Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
- 10.3. Research Assumption